DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: As a complement to these therapies aiming to restore dystrophin expression, many compounds targeting secondary effects of dystrophin deficiency or looking for alternatives to dystrophin are also under evaluation.